Compare British American Tobacco PLC (BTI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Neurocrine Biosciences Inc — how do they compare? British American Tobacco PLC trades at $57 (market cap $122.36B), while Neurocrine Biosciences Inc trades at $156 (market cap $16.46B). The key difference: British American Tobacco PLC is far larger — about 7.4× Neurocrine Biosciences Inc's market cap, and British American Tobacco PLC pays a 5.88% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BTI | NBIX | |
|---|---|---|
Market Cap | $122.36B | $16.46B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $185.50 |
52-Week Low | $50.39 | $123.10 |
Enterprise Value | $166.31B | $16.48B |
Dividend Yield | 5.88% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
